Most Read Articles
07 May 2021
Both denosumab and alendronic acid fall short of reducing disease progression in patients with calcific aortic stenosis, a study has shown.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 06 May 2021
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
6 days ago
The effect of cannabidiol (CBD) in the treatment of patients with Lennox–Gastaut syndrome may occur within 7 days of initiation, and most adverse events resolve within a 14-week period, a study reports.

Silicone gel in the treatment of surgical scars

22 Oct 2019
Topical silicone gel is considered first-line therapy against scars and is used particularly for the treatment of elevated scars,such as hypertrophic and keloid scars. In this report, Dr Yong shares his clinical experience of using silicone gel as part of his scar management strategies.

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
07 May 2021
Both denosumab and alendronic acid fall short of reducing disease progression in patients with calcific aortic stenosis, a study has shown.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 06 May 2021
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
6 days ago
The effect of cannabidiol (CBD) in the treatment of patients with Lennox–Gastaut syndrome may occur within 7 days of initiation, and most adverse events resolve within a 14-week period, a study reports.